BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:26 PM
 | 
Jun 27, 2008
 |  BC Extra  |  Clinical News

Merck's telcagepant meets migraine endpoints

Merck (NYSE:MRK) said both doses of oral telcagepant ( MK-0974) significantly improved all five primary endpoints vs. placebo in a Phase III trial to treat acute migraine pain. The double-blind trial of the calcitonin gene-related peptide (CGRP) antagonist in 1,380 patients evaluated 150 and...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >